Helicobacter pylori infection and extragastric disorders in children: A critical update

Table 2 Baseline clinical features of children with chronic idiopathic thrombocytopenic purpura

Study	No. of patients	Male/female	Disease duration	Concomitanttherapy1	Diagnosis ofH. pyloriinfection	No. of infected children	No. of infected untreated children	Age of infected children, yr		Age of uninfectedchildren, yr	PLT count (× 109/L) among treatedH. pylori-positive/No. of children	PLT count (× 109/L) amongH. pylori-negative/No. of children	PLT count (× 109/L) among untreatedH. pylori-positive/No. of children
Jaing et al[95] 2003, Taiwan	22	13/9	29 ± 26 mo	13/22	Stool antigen	9	0	5 (1-13.5)		8.7 (1.8-17.3)	< 50/9	50-99/3 < 50/10	-
Rajantie et al[96] 2003, Finland	17	7/10	3.9 (0.6-14.5) yr	NR	H. pylori antibodies and/or 13C UBT	0	0		3.82 (0.3-14.3)		-	-	-
Hayashi et al[97] 2005, Japan	10	6/4	4.2 ± 3.2 yr	NR	Stool antigen and/or 13C UBT	2	1	9 (7-11)		9 (4-14)	50-99/1	50-99/4 < 50/4	< 50/1
Yetgin et al[98] 2005, Turkey	35	NR	≥ 2 yr	NR	H. pylori antibodies and/or histology/13C UBT	11	0	NR	NR	NR	< 50/11	< 50/24	-
Loffredo et al[99] 2007, Italy	39	13/26	> 6 mo	-	H. pylori antibodies, 13C UBT, or stool antigen	8	0		112 (4.4-17)		< 100/8	< 100/31	-
Neefjes et al[100] 2007, Netherlands	47	18/29	> 1 yr	-	Stool antigen	3	0		≤ 162		< 100/3	< 100/44	-
Wu et al[101] 2007, Taiwan	32	18/14	NR	32/32	Stool antigen	6	6	5.13 (1.9-9.8)		4.13 (0.2-13.5)	-	8.8 ± 11.3/26	5.5 ± 4.7/6
Bisogno et al[102] 2008, Italy	24	9/15	1.2 (0.6-24) yr	-	Stool antigen, 13C UBT	8	0	13.2 (4.6-25.1)	12.52 (2-25.1)	10.8 (2-16.5)	< 50/8	50-99/3 < 50/13	-
Hamidieh et al[103] 2008, Iran	31	14/17	2.3 ± 1.7 yr	NR	13C UBT	4	0		8.923 (3.5-14)		100/1 < 50/3	NR	-
Treepongkaruna et al[105] 2009, Thailand	16	7/9	1.2-9.5 yr	9/16	13C UBT	164	9	7.4 -16.5			23 (3.0-84.0)/7	-	34 (3.0-86.0)/9
Ferrara et al 2009[104], Italy	24	14/10	1.8 (1.3-2.3) yr	-	Stool antigen	8	0	7.5 (6.7-10.2)		7.8 (5.4-10.7)	29.8 ± 3.8/8	33.5 ± 3.8/16	-
Russo et al 2011[106], Italy	37	12/25	> 1 yr	-	Stool antigen	374	-	12.3 ± 4.3513.6 ± 2.96	-	-	26.5 ± 22.3/33527.7 ± 22.3/46	-	-

Results are given as mean plus or minus standard deviation, or as median (range), unless otherwise noted.

¹Concomitant therapy included steroids or other immunosuppressive therapies;

²Age of all patients;

³Mean (range);

⁴This series included only infected patients;

⁵Children with successful eradication;

⁶Children with unsuccessful eradication. PLT: Platelet; H. pylori: Helicobacter pylori; NR: Not reported.